Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Preecalmpsia
Phase Not Applicable
Enrollment 52
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Preeclampsia with severe features remains a leading contributor to maternal morbidity and mortality, particularly in low- and middle-income countries. It is defined by hypertension and involvement of multiple organ systems, including renal, hepatic, hematologic, and neurologic pathways. The interplay of endothelial dysfunction, capillary leakage, and disrupted fluid balance in these patients increases their susceptibility to perioperative pulmonary complications. Although respiratory complications in preeclampsia are clinically significant, the true incidence of postoperative diaphragmatic dysfunction in women with severe disease is not well established. Existing literature largely emphasizes general respiratory failure, pulmonary edema, or the need for mechanical ventilation, rather than specifically evaluating diaphragmatic performance with objective methods such as ultrasound. The current study sought to determine the incidence and identify risk factors for postoperative diaphragmatic dysfunction in women with severe preeclampsia following cesarean delivery.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • The incidence of postoperative diaphragmatic dysfunction (Diaphragmatic excursion is measured before and 24 hours after surgery.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-03-09
Completion: 2026-12-31
Eligibility
Age: 20 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 52 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Cairo University
Contact Information
Study Contact:
Mina Adolf Helmy, MD
01275716942
minaadolf1988@cu.edu.eg
Mina Adolf Helmy, MD
01275716942
minaadolf1988@cu.edu.eg
Cairo University Hospitals
Mina
Cairo University Hospitals
Interventions
N/A
Study Locations (1 sites)
Cairo University Hospitals, Cairo, Egypt
Eligibility Criteria
Inclusion Criteria: * Patients with severe preeclampsia undergoing cesarean section * Gestational age \> 32 weeks Exclusion Criteria: * • Age \< 20 years. * Diabetic * Patients with neuromuscular diseases. * Patient refusal. * Contraindications to magnesium sulphate administration * Inability to obtain adequate ultrasound views
Conditions Kidney Transplant Recipient, Kidney Tran...
Phase Not Applicable
Enrollment 60
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

* To determine the incidence of arterial inflow problems and venous outflow problems as causes of impaired renal function and/or treatment-resistant hypertension after kidney transplantation, when all kidney-transplant recipients in Denmark are evaluated according to uniform, well-defined clinical criteria. * To investigate the efficacy and safety of catheter-based balloon treatment (percutaneous transluminal angioplasty, PTA) for these vascular complications, of which transplant renal artery stenosis is by far the most common. * To assess whether novel imaging and functional diagnostic methods can predict treatment response.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Diagnostic Test: Catheter-based angiography — Catheter-based angiography performed in accordance with the study protocol.
  • Diagnostic Test: Measurement of translesional pressure gradients — Measurement of translesional pressure gradients performed in accordance with the study protocol.
  • Diagnostic Test: Intravascular ultrasound (IVUS) — Intravascular ultrasound (IVUS) performed in accordance with the study protocol.
  • Procedure: Percutaneous transluminal angioplasty (PTA) — Percutaneous transluminal angioplasty (PTA) is performed in accordance with the study protocol. As a general principle, bare-metal stents (BMS) are used. Drug-eluting stents (DES) may be considered when the arterial lumen diameter is \< 4-5 mm. In stenoses where stent placement carries a risk of side-branch occlusion, PTA is performed without stent implantation and most often with a drug-coated balloon (DCB).

Primary Outcomes

  • Change in measured glomerular filtration rate (mGFR). (Baseline and 3 months post-PTA.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-05-22
Completion: 2031-06-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Aarhus
Collaborators: Aarhus University Hospital, Rigshospitalet, Denmark, Odense University Hospital, Aalborg University Hospital, Gødstrup Hospital, Holbaek Sygehus, Amsterdam UMC, The Augustinus Foundation, Denmark.
Principal Investigators:
  • Mark Reinhard, MD, PhD (PRINCIPAL_INVESTIGATOR) - Aarhus University Hospital
Contact Information
Study Contact:
Mark Reinhard, MD, PhD
+45 40460321
markrein@rm.dk
Henrik Birn, MD, DMSc
hb@clin.au.dk
Mark Reinhard, MD, PhD
markrein@rm.dk
Aarhus University Hospital
Interventions
  • Diagnostic Test: Catheter-based angiography — Catheter-based angiography performed in accordance with the study protocol.
  • Diagnostic Test: Measurement of translesional pressure gradients — Measurement of translesional pressure gradients performed in accordance with the study protocol.
  • Diagnostic Test: Intravascular ultrasound (IVUS) — Intravascular ultrasound (IVUS) performed in accordance with the study protocol.
  • Procedure: Percutaneous transluminal angioplasty (PTA) — Percutaneous transluminal angioplasty (PTA) is performed in accordance with the study protocol. As a general principle, bare-metal stents (BMS) are used. Drug-eluting stents (DES) may be considered when the arterial lumen diameter is \< 4-5 mm. In stenoses where stent placement carries a risk of side-branch occlusion, PTA is performed without stent implantation and most often with a drug-coated balloon (DCB).
Study Locations (3 sites)
Aarhus University Hospital, Aarhus, 8200 Denmark
Rigshospitalet, Copenhagen, 2100 Denmark
Odense University Hospital, Odense, 5000 Denmark
Eligibility Criteria
Inclusion Criteria: 1\. At least one of the following clinical criteria (1 or 2) must be fulfilled: 1. Graft dysfunction, defined by at least one of the following: * Acute reduction in estimated glomerular filtration rate (eGFR) \>15% on two consecutive measurements at least 2 weeks apart, with other causes excluded (rejection, obstruction, infection). * eGFR \<50% of the expected value 30 days after kidney transplantation of unknown cause. * Decline in eGFR \>30% after initiation of an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker. 2. Persistent resistant hypertension for more than 6 weeks after kidney transplantation, defined as: * 24-hour ambulatory systolic blood pressure \>130 mmHg despite treatment with at least three classes of antihypertensive medication at maximally tolerated doses (including diuretics, if tolerated). Together with at least one of the following radiological criteria: 1. CT or MR angiography demonstrating a lumen reduction ≥50%. 2. Doppler ultrasound showing: 1. Peak systolic velocity in the renal artery ≥200 cm/s and a renal renal ratio (velocity at stenosis / velocity in distal artery) \>4. 2. Acceleration time \>70 ms in intrarenal arteries. 2\. In cases of strong clinical suspicion of a vascular complication where CT or MR angiography cannot reliably exclude graft artery or vein stenosis, patients may be referred for confirmatory invasive investigations. Before PTA, catheter-based angiography and translesional pressure measurements are performed to confirm whether the patient meets the radiological eligibility criterion for PTA: 1. Stenosis ≥70%. 2. Stenosis 50-69% if at least one of the following criteria is met: * Mean translesional pressure gradient ≥10 mmHg. * Systolic pressure gradient ≥20 mmHg. * Renal Pd/Pa ≤0.8. * If pressure measurements cannot be obtained, treatment is based on the operator's clinical judgement. Exclusion Criteria: 1. Inability to provide informed consent. 2. Concurrent biopsy demonstrating rejection requiring treatment. 3. Pregnancy. 4. Previous PTA of the same vessel. 5. Patients unable to tolerate any form of antithrombotic therapy and therefore not eligible for stent placement.
Conditions Diabetes Mellitus, Type 2
Phase PHASE1
Enrollment 162
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The main objective of this trial is to assess the safety and tolerability of AMG 127 as single dose and multiple doses in healthy participants and participants with type 2 diabetes mellitus (T2DM).

Design

Study type: Interventional Phases: Phase1 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: AMG 127 — AMG127 will be administered as either a SC injection or as an IV infusion.
  • Drug: Placebo — Placebo will be administered as either a SC injection or as an IV infusion.

Primary Outcomes

  • Number of Treatment-Emergent Adverse Events (TEAEs) (Part A, SAD: Day 1 to end of trial (up to approximately 58 days); Part B, MAD: Day 1 to end of trial (up to approximately 86 days); Part C, PoM: Day 1 to end of trial (up to approximately 87 days))
  • Number of Serious Adverse Events (SAEs) (Part A, SAD: Screening to end of trial (up to approximately 86 days); Part B, MAD: Screening to end of trial (up to approximately 114 days); Part C, PoM: Screening to end of trial (up to approximately 115 days))
  • Number of Adverse Events Leading to Study Discontinuation (Part A, SAD: Day 1 to end of trial (up to approximately 58 days); Part B, MAD: Day 1 to end of trial (up to approximately 86 days); Part C, PoM: Day 1 to end of trial (up to approximately 87 days))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2026-06-11
Completion: 2027-10-02
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 162 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Amgen
Principal Investigators:
  • MD (STUDY_DIRECTOR) - Amgen
Contact Information
Study Contact:
Amgen Call Center
866-572-6436
medinfo@amgen.com
Interventions
  • Drug: AMG 127 — AMG127 will be administered as either a SC injection or as an IV infusion.
  • Drug: Placebo — Placebo will be administered as either a SC injection or as an IV infusion.
Study Locations (2 sites)
Orange County Research Center, Lake Forest, California 92630 United States
Translational Clinical Research LLC, Aventura, Florida 33180 United States
Eligibility Criteria
Inclusion Criteria for Part A and B * Participant must be 18-65 years of age * Participant must be overtly healthy Inclusion Criteria for Part C * Participant must be 40-75 years of age * Confirmed diagnoses of T2DM Exclusion Criteria for Part A and B * History of hypotension, syncope, or orthostatic intolerance * Systolic blood pressure \>140 millimeters of mercury (mmHg) or diastolic blood pressure \>90 mmHg Exclusion Criteria for Part C * Hemoglobin A1c (HbA1c) \>10% within the last 3 months * History of hypotension, syncope, or orthostatic intolerance * Systolic blood pressure \>160 mmHg or diastolic blood pressure \>100 mmHg

TIS for NSSI in Adolescent Depression

NCT07554755
Recruiting
Conditions Temporal Interference Stimulation, Non S...
Phase NA
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Temporal Interference Stimulation (TIS) has been successfully used to help patients with depression. However, its role in alleviating self injuries remained uncertain. This trial will compare the effectiveness of TIS to a placebo control on non-suicidal self injury (NSSI) in patients with major depressive disorder(MDD).

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Device: Active Temporal Interference Stimulation (TIS) — Active stimulation to the right subgenual anterior cingulate cortex; 2 sessions per day, 30 minutes per session, including a 30-second current ramp-up at the beginning and a 30-second ramp-down at the end, for 5-7 days.
  • Device: Sham Temporal Interference Stimulation (TIS) — Sham stimulation had only 30 seconds of current ramping-up and ramping-down at the beginning and end of the stimulation, respectively, to simulate the sensation of actual stimulation.

Primary Outcomes

  • Changes in the Adolescent Non-Suicidal Self-Injurious Behavior Assessment Questionnaire (ANSAQ) (Baseline, the day after the end of TIS, 2 weeks after the end of TIS, 4 weeks after the end of TIS, 8 weeks after the end of TIS)
  • Changes in the 17-item Hamilton Rating Scale for Depression (HAMD-17) (Baseline, the day after the end of TIS, 2 weeks after the end of TIS, 4 weeks after the end of TIS, 8 weeks after the end of TIS)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-04-30
Completion: 2027-01-31
Eligibility
Age: 12 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The Second Hospital of Anhui Medical University
Contact Information
Study Contact:
Yanghua Tian, PhD
+86-13955188448
tianyh@ahmu.edu.cn
Hongping Wang
+86-18256001073
medstuwhp@126.com
Yanghua Tian, PhD
0551 6599 7278
tianyh@ahmu.edu.cn
The Second Affiliated Hospital of Anhui Medical University
Interventions
  • Device: Active Temporal Interference Stimulation (TIS) — Active stimulation to the right subgenual anterior cingulate cortex; 2 sessions per day, 30 minutes per session, including a 30-second current ramp-up at the beginning and a 30-second ramp-down at the end, for 5-7 days.
  • Device: Sham Temporal Interference Stimulation (TIS) — Sham stimulation had only 30 seconds of current ramping-up and ramping-down at the beginning and end of the stimulation, respectively, to simulate the sensation of actual stimulation.
Study Locations (1 sites)
The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022 China
Eligibility Criteria
Inclusion Criteria: 1. Meet the DSM-5 (Diagnostic and Statistical Manual of Mental Disorders 5th Edition) diagnostic criteria for major depressive disorder. 2. Patients aged 12-22 years with at least one guardian to monitor them for 3 months 3. HAMD-17 Total score ≥18 4. Patients who had two or more non-suicidal self-injury behaviors meeting the 5.DSM-5 diagnostic criteria in the 2 weeks before admission (NSSI behavior of more than 5 days in the past year) 6.Obtain informed consent from patients and guardians \- Exclusion Criteria: 1. Substance abusers such as psychoactive drugs or alcohol. 2. Severe physical disability and unable to complete follow-up. 3. Comorbid other major mental illnesses that meet the DSM-5 criteria, such as bipolar disorder, schizophrenia, mental retardation, dementia, severe cognitive impairment, attention deficit hyperactivity disorder, etc. 4. Suffering from any severe physical disease, neurological disease, traumatic brain injury, etc, that affects the structure or function of the brain in the lifetime. Unable to read, understand and complete the assessment or to cooperate with the investigators. 5. Any implants covering a pacemaker, metallic or magnetic objects in the body, or other conditions not suitable for TIS. 6. Those who have received systematic psychotherapy (interpersonal relationship therapy, dynamic therapy, cognitive behavioral therapy) or TMS within 3 months before baseline. 7. Other examination abnormalities considered to be inappropriate by investigators. \-
Conditions HR+ HER2- Breast Cancer
Phase PHASE1, PHASE2
Enrollment 32
Locations 7 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The study is a Phase 1b/2, multi-center, open-label, dose escalation trial evaluating the safety and preliminary efficacy of sapanisertib and serabelisib (PIKTOR) with fulvestrant and/or other anticancer therapies in participants with HR+/HER2- advanced/metastatic breast cancer.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Serabelisib — Serabelisib is a selective, small molecule inhibitor of PI3Kα.
  • Drug: Sapanisertib — Sapanisertib is a small molecule inhibitor of the mammalian mTOR serine/threonine kinase.
  • Drug: Fulvestrant — Fulvestrant is a first-in-class SERD.

Primary Outcomes

  • Safety and tolerability of drugs by assessment of adverse events (AEs) / serious adverse events (SAEs) (2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2026-04-22
Completion: 2033-05
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 32 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Faeth Therapeutics
Contact Information
Study Contact:
Medical Monitor
(708) 406-9282
clinicaltrials@faeththerapeutics.com
Interventions
  • Drug: Serabelisib — Serabelisib is a selective, small molecule inhibitor of PI3Kα.
  • Drug: Sapanisertib — Sapanisertib is a small molecule inhibitor of the mammalian mTOR serine/threonine kinase.
  • Drug: Fulvestrant — Fulvestrant is a first-in-class SERD.
Study Locations (7 sites)
START Los Angeles, Los Angeles, California 90025 United States
Rocky Mountain Cancer Centers, Lone Tree, Colorado 80124 United States
Oncology Associates of Oregon, Springfield, Oregon 97477 United States
SCRI Oncology Partners, Nashville, Tennessee 37203 United States
Texas Oncology - Central/South, Austin, Texas 78731 United States
START San Antonio, San Antonio, Texas 78229 United States
Texas Oncology - San Aantonio, San Antonio, Texas 78240 United States
Eligibility Criteria
Inclusion Criteria: * Histologically confirmed diagnosis of HR+/HER2- breast cancer. * Documented evidence of advanced or recurrent disease that is not amenable to surgery/radiation for curative intent. * Participant has received at least one prior systemic therapy. * At least 1 measurable or evaluable target lesion according to RECIST v1.1 * Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1 at Screening. * Non-pregnant, non-lactating females who are postmenopausal, surgically sterile or who agree to use effective contraceptive methods. Exclusion Criteria: * Participants with triple-negative breast cancer. * Participants with central nervous system metastases are not eligible, unless they have completed local therapy and have discontinued the use of corticosteroids for this indication for at least 4 weeks before starting treatment in this study. * Active malignancy (except for breast cancer, definitively treated in-situ carcinomas \[e.g., breast, cervix, bladder\], or basal or squamous cell carcinoma of the skin) within the past 24 months prior to treatment. Fully resected localized malignancies are eligible. * Gastric feeding tube (gastrostomy tube), gastrointestinal malabsorption, gastrointestinal anastomosis, bowel obstruction, or any other condition that might affect the absorption of study treatment. * Significant cardiovascular impairment. * Active, uncontrolled infection. * Concurrent participation in another therapeutic clinical trial. * Prior radiation therapy within 21 days prior to start of study treatment. * Participants who have received a prior PI3K, AKT, mTORC1/2, or dual PI3K/mTOR inhibitor. * Strong CYP3A4 inhibitors, strong CYP1A2 inhibitors or CYP1A2 inducers, or clinically significant CYP3A4 inducers within 7 days before the first dose of study intervention, or participants who require treatment with strong CYP3A4 inhibitors or inducers during the study. * Prolongation of QTc interval to \>480 ms. * Type 1 or Type 2 diabetes mellitus on insulin.
Conditions Prediabetes, Type 2 Diabetes (T2DM)
Phase PHASE3
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study tests whether taking a weekly dose of vitamin D, with the dose adjusted to reach a target blood vitamin D level, can help control blood sugar levels in adults at high risk of developing type 2 diabetes (prediabetes). Research suggests that vitamin D may play a role in blood sugar control. The goal of this study is to see whether adjusting the dose of vitamin D to reach a specific blood vitamin D level improves blood sugar control compared with a placebo (a look-alike pill without vitamin D). One hundred adults aged 30 to 74 with prediabetes will take part. Participants will be randomly assigned (by chance) to receive either weekly vitamin D supplements or a placebo. Neither the participants nor the research team will know which group a participant is in during the study. Participants in the vitamin D group will start with one specific dose. After three months, a blood test will be used to decide whether the dose should stay the same or be increased to reach the target vitamin D level. Participants in the placebo group will continue taking the placebo each week. All participants will be followed for about 18 months. During the study, they will attend scheduled study visits, have blood tests, and wear a continuous glucose monitor, a small device that measures blood sugar levels throughout the day and night. The research team will also make periodic phone calls to check on health changes, medication use, and study participation. The main outcome of the study is the proportion of time that the participants' blood sugar levels remains in a healthy range.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Vitamin D (Cholecalciferol ) — Vitamin D (cholecalciferol) will be administered orally once weekly for approximately 18 months. The vitamin D will be provided in liquid form in an ampule. Participants in the intervention group will begin with a dose of 25,000 IU per week. A blood vitamin D level will be measured at 3 months, and the dose will be increased to 50,000 IU per week for participants whose results are below the study target.
  • Drug: Placebo — Placebo will be administered orally once weekly for approximately 18 months. The placebo will be provided in an ampule and will be matched in appearance, dosing schedule, and duration to the active study medication.

Primary Outcomes

  • Time-in-normoglycemia 140 (Assessed every 6 months from enrollment to the end of the study at 18 months.)
  • Time-In-Normoglycemia 126 (Assessed every 6 months from enrollment to the end of the study at 18 months.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2026-08-04
Completion: 2031-03
Eligibility
Age: 30 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Tufts Medical Center
Collaborators: Abiogen Pharma
Contact Information
Study Contact:
Tufts Medical Center Endocrine Research Team
617-636-3232
endocrine-research@tuftsmedicine.org
Tufts Medical Center Endocrine Research Team
617-636-3232
endocrine-research@tuftsmedicine.org
Tufts Medical Center
Anastassios Pittas, MD
Tufts Medical Center
Interventions
  • Drug: Vitamin D (Cholecalciferol ) — Vitamin D (cholecalciferol) will be administered orally once weekly for approximately 18 months. The vitamin D will be provided in liquid form in an ampule. Participants in the intervention group will begin with a dose of 25,000 IU per week. A blood vitamin D level will be measured at 3 months, and the dose will be increased to 50,000 IU per week for participants whose results are below the study target.
  • Drug: Placebo — Placebo will be administered orally once weekly for approximately 18 months. The placebo will be provided in an ampule and will be matched in appearance, dosing schedule, and duration to the active study medication.
Study Locations (1 sites)
Tufts Medical Center, Boston, Massachusetts 02111 United States
Eligibility Criteria
Inclusion Criteria: 1. High-risk prediabetes ("at high risk for type 2 diabetes") defined by meeting the following 2 prediabetes criteria established by the American Diabetes Association (ADA) in the 2010 clinical practice guidelines: 1. Fasting plasma glucose (FPG) 100-125 mg/dL, inclusive 2. Hemoglobin A1c (HbA1c) 5.7-6.4%, inclusive 2. Age 30-74 years, inclusive 3. Body Mass Index ≥ 23.0 and ≤ 35.0 kg/m2 4. Provision of signed and dated written informed consent prior to any study procedures. Exclusion Criteria: 5. History of diabetes (ICD10 diabetes code E08.X through E13.X) or meeting a diabetes glycemic criterion at screening, as defined by the ADA guidelines (FPG ≥ 126 mg/dL or HbA1c ≥ 6.5%). 6. History (past 2 years) of hyperparathyroidism, symptomatic or asymptomatic (i.e., radiographic) nephrolithiasis or hypercalcemia. 7. Any medical condition (past 2 years) that in the opinion of the site investigator may increase risk for nephrolithiasis or hypercalcemia during the trial (e.g., sarcoidosis). 8. If older than 70 years, history (past 1 year) of a fall. 9. Use of tanning devices within 12 weeks of the baseline visit and unwilling to stop use of tanning devices for the duration of the study. Medications and Supplements 10. Use (past 6 months) of hypoglycemic pharmacotherapy (oral or injectable medication approved by the FDA for type 2 diabetes) for any condition (e.g., prediabetes, diabetes, polycystic ovarian syndrome, MASLD, sleep apnea) or any other medication that may affect glycemia (e.g., hydroxychloroquine) 11. Current use of medications approved by the FDA for weight management (e.g., incretin receptor agonists) or planned use during the study. 12. Use of supplements containing vitamin D at total doses higher than 1000 IU/day within 8 weeks of the baseline visit and unwillingness to limit vitamin D supplementation dosage to no higher than 1000 IU/day during the study. Because supplements vary widely in vitamin D content (e.g., may include cod liver or cod liver oi), participants will bring all supplements to the site for a review by the research team. 13. Use of supplements containing calcium at total doses higher than 600 mg/day within 1 week of the baseline visit and unwillingness to limit calcium supplementation dosage to no higher than 600 mg/day during the study. 14. Current use of medications or conditions (e.g., untreated celiac disease) that would interfere with the absorption or metabolism of vitamin D. 15. Use of an anticonvulsant drug started within 6 months of screening. Stable regimen of anticonvulsants is allowed. 16. History of intolerance to vitamin D supplements, allergic to any content of the study drug or unwilling to take vitamin D supplements (e.g., someone who eats a vegan diet and would object to the cholecalciferol ingredient which is produced from cholesterol extracted from sheep wool harvested from healthy living sheep). Other Medical History 17. Severe symptomatic cardiovascular disease based on history (unstable angina, dyspnea on exertion, paroxysmal nocturnal dyspnea, arrhythmia, congestive heart failure NYHA class II or higher, claudication) 18. History (past 1 year) of myocardial infarction, percutaneous coronary intervention, or coronary artery bypass graft. 19. History (past 1 year) of cerebrovascular disease (stroke, transient ischemic attack). 20. Any type of cancer (past 5 years) except for basal cell skin cancer. Prostate cancer (for men over age 55) or well-differentiated thyroid cancer not expected to require treatment (except for suppression with thyroid hormone) over the next 3 years, are not exclusions. People with history of squamous cell cancer of the skin, which was completely excised and with no evidence of metastases, are eligible. 21. History (past 6 months) of treatment with oral (for \> 7 days) or intravenous glucocorticoids or disease likely to require oral or intravenous glucocorticoid therapy during the study. Inhaled glucocorticoid use is not an exclusion. Epidural or intra-articular glucocorticoid injections are not exclusions, but study visits need to be conducted at least two weeks after the injection. Persons with adrenal insufficiency treated with physiologic doses of glucocorticoids who are otherwise stable are not excluded. 22. History (past 1 year) of substance abuse or unstable psychiatric disorder that in the opinion of the site investigator would impede competence or adherence with study procedures or hinder completion of the study or increase risk. 23. History of bariatric surgery (e.g., Roux-en-Y gastric bypass, gastric sleeve) or planned bariatric surgery in the next 2 years. 24. Extreme (over 18 hours) intermittent fasting diets because prolonged fasting downregulates CYP2R1 activity. 25. A life-threatening event within 30 days of screening or currently planned major surgery. 26. Any other active medical condition (including but not limited to liver disease, wasting illness, HIV, tuberculosis, oxygen-dependent chronic obstructive pulmonary disease, organ transplant, Cushing's syndrome) that in the opinion of the site investigators would interfere with the study objectives, impede competence or adherence with study procedures or increase risk. 27. Uncontrolled hypertension (systolic blood pressure \> 160 mm Hg or diastolic blood pressure \> 100 mm Hg). 28. Poor venous access. Laboratory Evaluation 29. Serum liver transaminase higher than 3 times the normal range for the clinical site's laboratory, within 18 months of screening. 30. Anemia (hematocrit \< 32 for women, \< 36 for men), whole blood transfusion (within 18 months of screening) or chronic requirement, whole blood donation (within 3 months of screening) or other condition (hemolysis, hemoglobinopathy) rendering HbA1c results unreliable as indicator of chronic glycemia. Participants who donate platelets are not excluded. 31. Low platelet count (\< 100,000) within 18 months of screening. 32. Chronic kidney disease, defined as estimated glomerular filtration rate \[GFR\] \< 50 mL/min per 1.73 m2 from creatinine level and GFR calculated by the new Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations that omit race within 18 months of screening. 33. Hypercalcemia, defined as serum calcium concentration ≥ upper limit of normal within 18 months of screening. 34. Hypercalciuria, defined as spot urine (morning void) calcium-creatinine ratio \> 0.275 within 18 months of screening. 35. Baseline serum 25(OH)D level greater than 100 ng/mL. Other 36. Participation (within 30 days of screening) in another interventional research study, and unwillingness to refrain from participating in another intervention study during the study. 37. Previous randomization in the study. Participants who did not qualify after screening may be screened again if the prior reason for exclusion has been addressed (e.g., high blood pressure is treated). 38. Any other reason that in the opinion of the site investigator would interfere with the study objectives, impede adherence with study procedures or hinder completion of the study or increase risk. Women only 39. Pregnancy (past 1 year by report or positive pregnancy test at screening), intent to become pregnant in the next 2 years. History of gestational diabetes is not an exclusion criterion. 40. Currently breastfeeding. 41. Use of oral contraceptives or menopausal hormone therapy started within 3 months of baseline. . Continuous Glucose Monitoring specific 42. Regular use of personal CGM and unwillingness to refrain from using personal CGM for the duration of the study. 43. Use of hydroxyurea or regular use of high doses of acetaminophen (may impact CGM). 44. Extensive skin changes (e.g., skin breakdown, rash) making CGM sensor use problematic. 45. Significant skin sensitivity to adhesive (making CGM sensor unfeasible).
Conditions Breast Cancer, HER2-positive Breast Canc...
Phase PHASE2
Enrollment 60
Locations 7 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Thie purpose of this study is to find out whether a personalized treatment approach-using a series of ctDNA tests along with standard imaging scans to help decide when to step up (escalate) or decrease (de-escalate) sequential treatments (given one after another)-combined with local therapies (which treat cancer in a specific part of the body) and treatments that prevent cancer from spreading to the central nervous system (CNS; including the brain and spinal cord) can result in long-lasting remission and possibly cure some participants with HER2+ metastatic breast cancer.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Diagnostic Test: Personalis NeXT Personal — The use of this assay is expected to optimize treatment without introducing significant new risks or deviating from approved therapeutic protocols.
  • Diagnostic Test: Natera Signatera — The use of this assay is expected to optimize treatment without introducing significant new risks or deviating from approved therapeutic protocols.
  • Drug: fam-trastuzumab deruxtecan-nxki (T-DXd) — T-DXd is a HER2-targeting antibody drug conjugate that consists of an anti-HER2 antibody.
  • Drug: pertuzumab, called T-DXd+P — intravenous (IV) infusion

Primary Outcomes

  • Proportion of participants who maintain Complete Response/CR and Molecular Complete Response/mCR (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-03-04
Completion: 2030-03-04
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Memorial Sloan Kettering Cancer Center
Principal Investigators:
  • Pedram Razavi, MD, PhD (PRINCIPAL_INVESTIGATOR) - Memorial Sloan Kettering Cancer Center
Contact Information
Study Contact:
Pedram Razavi, MD, PhD
646-888-4821
razavip@mskcc.org
Atif Khan, MD
848-225-6334
khana7@mskcc.org
Pedram Razavi, MD, PhD
646-888-4821
Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)
Interventions
  • Diagnostic Test: Personalis NeXT Personal — The use of this assay is expected to optimize treatment without introducing significant new risks or deviating from approved therapeutic protocols.
  • Diagnostic Test: Natera Signatera — The use of this assay is expected to optimize treatment without introducing significant new risks or deviating from approved therapeutic protocols.
  • Drug: fam-trastuzumab deruxtecan-nxki (T-DXd) — T-DXd is a HER2-targeting antibody drug conjugate that consists of an anti-HER2 antibody.
  • Drug: pertuzumab, called T-DXd+P — intravenous (IV) infusion
Study Locations (7 sites)
Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey 07920 United States
Memorial Sloan Kettering at Monmouth (Limited Protocol Activities), Middletown, New Jersey 07748 United States
Memorial Sloan Kettering at Bergen (Limited Protocol Activities), Montvale, New Jersey 07645 United States
Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities), Commack, New York 11725 United States
Memorial Sloan Kettering at Westchester (Limited Protocol Activities), Harrison, New York 10604 United States
Memorial Sloan Kettering Cancer Center (All Protocol Activites), New York, New York 10065 United States
Memorial Sloan Kettering at Nassau (Limited Protocol Activities), Uniondale, New York 11553 United States
Eligibility Criteria
Inclusion Criteria: * Male or female participants who are ≥18 years old with histologically confirmed diagnosis of unresectable locally advanced or MBC. * Stage IV at the diagnosis (i.e., de novo metastatic) as per AJCC 8. * HER2 IHC results of 3+. * Life expectancy of ≥12 weeks. * Must be deemed medically fit for surgery and be surgical candidates upfront, or potentially operable if there is response to induction therapy. * Must have measurable disease per PERCIST 1.0. * The participant (or legally acceptable representative if applicable) provides written informed consent for the trial. * Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. * Have adequate organ function as defined in the following table (Table 1). Specimens must be collected within 14 days prior to the start of study intervention. * A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies: * Is not a woman of childbearing potential (WOCBP) OR Is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of \<1% per year), with low user dependency, or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis), as described in Appendix 3 during the intervention period. The investigator should evaluate the potential for contraceptive method failure (i.e., noncompliance, recently initiated) in relationship to the first dose of study intervention. * A WOCBP must have a negative urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of beta-human chorionic gonadotropin \[β-hCG\]) within 72 hours before the first dose of study intervention. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. * Additional requirements for pregnancy testing during and after study intervention are located in Appendix 2.The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy. * Male participants are eligible to participate if they agree to the following during the intervention period and for at least 7 days after the last dose of therapy. * Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent OR must agree to use contraception unless confirmed to be azoospermic (vasectomized or secondary to medical cause) as detailed below: * Agree to use a male condom plus partner use of an additional contraceptive method when having penile-vaginal intercourse with a WOCBP who is not currently pregnant. Note: Men with a pregnant or breastfeeding partner must agree to remain abstinent from penile-vaginal intercourse or use a male condom during each episode of penile-vaginal penetration. * Criteria for known Hepatitis B and C positive subjects: Hepatitis B and C screening tests are required as per MSK policy but do not need to be repeated prior to study unless there is a known history of Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV) infection. * Participants who have active hepatitis B infection (defined as HBsAg positive and/or detectable HBV DNA) are eligible if they have received HBV antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to randomization. Participants should remain on anti-viral therapy throughout study intervention and follow MSK guidelines for HBV anti-viral therapy post completion of study intervention. * Participants with a history of HCV infection (defined as anti-HCV Ab positive and detectable HCV RNA) are eligible if HCV viral load is undetectable at screening. * Participants must have completed curative anti-viral therapy at least 4 weeks prior to randomization. Table 1 Adequate Organ Function Laboratory Values Hematological Absolute neutrophil count (ANC): ≥1500/µL Platelets: ≥100 000/µL Hemoglobin: ≥9.0 g/dL or ≥5.6 mmol/L Renal Creatinine OR Measured or calculated creatinine clearance (GFR can also be used in place of creatinine or CrCl): ≤1.5 × ULN OR ≥30 mL/min for participant with creatinine levels \>1.5 × ULN Hepatic Total bilirubin: ≤1.5 × ULN OR direct bilirubin ≤ULN for participants with total bilirubin levels \>1.5 × ULN AST (SGOT) and ALT (SGPT) Coagulation International normalized ratio (INR) OR prothrombin time (PT) Activated partial thromboplastin time (aPTT): ≤1.5 × ULN unless participant is receiving anticoagulant therapy as long as PT or aPTT is within therapeutic range of intended use of anticoagulants ALT (SGPT)=alanine aminotransferase (serum glutamic pyruvic transaminase); AST (SGOT)=aspartate aminotransferase (serum glutamic oxaloacetic transaminase); GFR=glomerular filtration rate; ULN=upper limit of normal. a Criteria must be met without erythropoietin dependency and without packed red blood cell (pRBC) transfusion within last 2 weeks. b Creatinine clearance (CrCl) should be calculated per institutional standard. Note: This table includes eligibility-defining laboratory value requirements for treatment; laboratory value requirements should be adapted according to local regulations and guidelines for the administration of specific chemotherapies. Exclusion Criteria: * Patients diagnosed with HER2+ breast cancer as per American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines with HER2 IHC results of 1-2+ and positive FISH or ISH * Prior exposure to anti-HER2 therapy of any kind or any systemic anti-cancer treatment of any kind for breast cancer. * Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 2 weeks prior to the first dose of study intervention. * Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in doses \>10 mg daily of oral prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug. Inhaled, intranasal, intra-articular, or topical steroid use are allowed. * Has a known additional malignancy that is progressing or has required active treatment within the past 3 years. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin or carcinoma in situ, excluding carcinoma in situ of the bladder, which have undergone potentially curative therapy are not excluded. * Has known CNS metastases and/or leptomeningeal carcinomatosis. * Has a history or evidence of active pneumonitis or interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease. * Has grade \>=3 neuropathy of any etiology. * Has an active infection requiring antibiotics. * Has a known history of Human Immunodeficiency Virus (HIV) infection. * Has an inability to swallow capsules or tablets. * Has a history or current evidence of any condition, therapy, or laboratory abnormality or other circumstance that might confound the results of the study, interfere with the participant's participation for the full duration of the study, such that it is not in the best interest of the participant to participate, in the opinion of the treating investigator. * Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial. * Is pregnant or breastfeeding or expecting to conceive within the projected duration of the study, starting with the screening visit through 120 days after the last dose of trial treatment. * Has had an allogenic tissue/solid organ transplant. * Has significant cardiovascular impairment within 12 months of the first dose of study drug: such as NYHA Class III or IV congestive heart failure, unstable angina, myocardial infarction, cerebral vascular accident, or cardiac arrhythmia associated wit
Conditions Breast Cancer Survivors, Endocrine Thera...
Phase NA
Enrollment 200
Locations 6 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this pragmatic, multicenter, randomized controlled trial is to evaluate the clinical effectiveness and safety of electroacupuncture and auricular acupressure for improving joint pain related to endocrine therapy in breast cancer patients. A total of 200 participants will be recruited and randomly assigned to one of three groups: the Electroacupuncture Group (n=80), the Auricular Acupressure Group (n=80), or the Waitlist Control Group (n=40), using a central stratified block randomization method. The primary objective is to compare changes in Worst Pain Item score among the three groups from baseline to the end of the treatment period, as measured by the Brief Pain Inventory-Short Form (BPI-SF). Secondary objectives include assessing pain interference, overall health status through the PROMIS scale, and quality of life specifically related to endocrine therapy using the FACT-ES. Additionally, the study will evaluate analgesic medication use (QAQ), patient expectations (Acupuncture Expectancy Scale), treatment adherence, and the occurrence of adverse events. By comparing these interventions, this study aims to generate high-quality evidence for the management of treatment-related arthralgia in breast cancer survivors.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Procedure: Electroacupuncture Group — Electroacupuncture is performed using the basic prescription combined with the prescription for the affected joints. Basic prescription: Shuigou (GV26), Hegu (LI4), Neiguan (PC6), Zusanli (ST36), Yanglingquan (GB34), Taichong (LR3), Sanyinjiao (SP6). On this basis, 1 to 4 additional acupoints are selected based on the two most severely affected joint areas. Needle selection: The acupuncture needles (40 or 75 mm x 0.25 mm gauge, and 40 mm x 0.18 mm gauge, Huatuo, Suzhou, China) will be used. An electroacupuncture stimulator (SDZ-V, Huatuo, Suzhou, China) will be used, delivering alternating frequencies of 2 Hz/10 Hz with no more than four electrode pairs simultaneously.
  • Procedure: Auricular Acupressure Group — The auricular acupressure protocol is formed by combining the basic auricular point prescription and the auricular point prescription corresponding to the affected joints. The basic points include Shenmen, Sympathetic, Endocrine, and Subcortex, while the additional points are selected by the acupuncturist based on the 1-2 joint regions with the most pain as reported by the patient. Once identified, Vaccaria seed (Zhongyan Taihe, Beijing, China) is taped onto the points until the patient perceives a distinct sensation of soreness or tenderness. Participants will be instructed to apply pressure to each ear three times per day, pressing each side for approximately 3 minutes per session. The auricular patches will be removed 2 to 4 days after during a follow-up visit at the clinic.

Primary Outcomes

  • The Worst Pain score of the Brief Pain Inventory-Short Form (Baseline, 4 weeks, 8 weeks, 12weeks, 16 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-04-01
Completion: 2027-12
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Principal Investigators:
  • Li Li (STUDY_CHAIR) - First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Contact Information
Study Contact:
Li Li
86+18222626653
lilitcm@foxmail.com
Jing Xue
xuejing506@163.com
xuan xuan Wang, PhD
18986024169
caidi87@163.com
Hubei Cancer Hospital
Interventions
  • Procedure: Electroacupuncture Group — Electroacupuncture is performed using the basic prescription combined with the prescription for the affected joints. Basic prescription: Shuigou (GV26), Hegu (LI4), Neiguan (PC6), Zusanli (ST36), Yanglingquan (GB34), Taichong (LR3), Sanyinjiao (SP6). On this basis, 1 to 4 additional acupoints are selected based on the two most severely affected joint areas. Needle selection: The acupuncture needles (40 or 75 mm x 0.25 mm gauge, and 40 mm x 0.18 mm gauge, Huatuo, Suzhou, China) will be used. An electroacupuncture stimulator (SDZ-V, Huatuo, Suzhou, China) will be used, delivering alternating frequencies of 2 Hz/10 Hz with no more than four electrode pairs simultaneously.
  • Procedure: Auricular Acupressure Group — The auricular acupressure protocol is formed by combining the basic auricular point prescription and the auricular point prescription corresponding to the affected joints. The basic points include Shenmen, Sympathetic, Endocrine, and Subcortex, while the additional points are selected by the acupuncturist based on the 1-2 joint regions with the most pain as reported by the patient. Once identified, Vaccaria seed (Zhongyan Taihe, Beijing, China) is taped onto the points until the patient perceives a distinct sensation of soreness or tenderness. Participants will be instructed to apply pressure to each ear three times per day, pressing each side for approximately 3 minutes per session. The auricular patches will be removed 2 to 4 days after during a follow-up visit at the clinic.
Study Locations (6 sites)
Hubei Cancer Hospital, Wuhan, Hubei 430079 China
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, Tianjin Municipality 300120 China
Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin, China
Tianjin Medical University Cancer Institute & Hospital, Tianjin, China
Affiliated Hospital of Qinghai University, Xining, China
Qinghai Provincial Hospital of Traditional Chinese Medicine, Xining, China
Eligibility Criteria
Inclusion Criteria: * Histologically or cytologically confirmed breast cancer, stage I-IV, according to the AJCC Cancer Staging Manual (8th edition); * Aged 18-75 years; * Experiencing joint pain attributed to endocrine therapy, including localized or generalized joint pain, with symptoms persisting for at least 1 week; * Completion of all planned surgeries, chemotherapy, and radiotherapy, with a scheduled continuation of endocrine therapy for at least 1 additional year; * Self-reported worst joint pain score of ≥3 on a 0-10 Visual Analogue Scale (VAS) during the past week; * Life expectancy ≥1 year; * Voluntarily sign the informed consent. Exclusion Criteria: * Bone metastases involving the same site as the affected joint attributed to endocrine therapy; * History of fracture or surgery involving the affected joints within the past 6 months; * Implanted electronic medical devices; * Not suitable for acupuncture, including but not limited to bleeding tendencies (e.g. coagulation disorders or purpura) or local skin lesions at the intended acupoint sites.
Conditions Breast Cancer (Triple Negative Breast Ca...
Phase NA
Enrollment 25
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment and work by blocking protein interactions that normally prevent the immune system from recognizing and destroying cancer cells. However, these agents, now approved for over 15 types of cancers and for both early-stage and metastatic disease, are capable of causing inflammation in any organ system of the body that can lead to organ damage, dysfunction, and even death in rare cases. Some patients may suffer acute and treatable complications like joint pain, but some may have irreversible complications like hypothyroidism that requires daily, life-long medication. It is therefore important to fully understand the different types of damage ICIs can cause to better monitor patients receiving ICI therapy. A rising concern from recent reports in the literature is that ICIs may weaken bone and increase the risk of fractures. In this study, the investigators aim to characterize how ICIs impact the bone by examining several factors in patients undergoing curative-intent ICI treatment either alone or in combination with chemotherapy: bone mineral density, bone volume, and markers of bone turnover in the blood. The study will use two imaging techniques to assess bone mineral density and volume. DXA (dual X-ray absorptiometry) imaging uses low-dose X-rays to measure how dense (or strong) bones are and is often used to diagnose or assess the risk of osteoporosis. High-resolution peripheral quantitative computed tomography (HRpQCT) is a 3D imaging technology that can quantify bone structure and volume and offers high resolution that can be used to assess bone in smaller bones of the peripheral skeleton. The investigators hypothesize that ICI treatment will weaken bones and increase the risk of fractures. As ICI therapy is relatively new, a rising number of patients may be at risk of fractures or have low bone density that is not being monitored because there are no guidelines in place notifying physicians of this potential risk to patients. This is study will provide important preliminary data that will be the basis for larger studies in the future aiming to better monitor and potentially treat bone weakening in patients treated with ICIs to reduce the pain, inconvenience, and complications from fragility fractures.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Device: Dual-Energy X-ray Absorptiometry (DXA) — Research participants undergo both DXA scans at baseline (within 1 month of starting immunotherapy), 4-6 months after starting immunotherapy, and after 12 months of immunotherapy
  • Device: High Resolution peripheral Quantitative Computed Tomography (HRpQCT) — Research participants undergo both HRpQCT scans at baseline (within 1 month of starting immunotherapy), 4-6 months after starting immunotherapy, and after 12 months of immunotherapy

Primary Outcomes

  • Change in BMD using DXA (At 12 months after starting immunotherapy)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-08-25
Completion: 2028-07-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 25 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Jessica Mezzanotte Sharpe
Contact Information
Study Contact:
Jessica Sharpe, MD, PhD
615-936-8422
jessica.m.sharpe@vumc.org
Jennifer Whisenant, PhD
615-936-8422
j.whisenant@vumc.org
Vanderbilt-Ingram Cancer Center
Jessica Sharpe, MD, PhD
Vanderbilt-Ingram Cancer Center
Interventions
  • Device: Dual-Energy X-ray Absorptiometry (DXA) — Research participants undergo both DXA scans at baseline (within 1 month of starting immunotherapy), 4-6 months after starting immunotherapy, and after 12 months of immunotherapy
  • Device: High Resolution peripheral Quantitative Computed Tomography (HRpQCT) — Research participants undergo both HRpQCT scans at baseline (within 1 month of starting immunotherapy), 4-6 months after starting immunotherapy, and after 12 months of immunotherapy
Study Locations (1 sites)
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee 37232 United States
Eligibility Criteria
Inclusion Criteria: 1. Age ≥ 18 years. 2. Patients planning to start or within the first four weeks of treatment with anti-PD-1 immune checkpoint inhibitor therapy either alone or in combination with chemotherapy for curative intent for a known cancer diagnosis (use of immunotherapy must be FDA-approved and not experimental). 3. Life expectancy of at least 12 months per the discretion of the treating physician. Exclusion Criteria: 1. Patients ineligible for anti-PD-1 therapy. 2. Patients with metastatic disease. 3. Patients planning treatment with dual immune checkpoint inhibitor therapy. 4. Bony fractures in the pelvis, bilateral hips/femurs, thoracic spine, or lumbar spine. 5. Known osteoporosis or osteopenia. 6. Planned or previous treatment with denosumab, zoledronic acid, or other bisphosphonate therapy in the last six months. 7. Parathyroid gland disorders, rheumatoid arthritis (unless well-controlled off active biologic therapy without chronic steroid use), CKD stage IV/V, or ESRD. 8. Inability to comply with study procedures. 9. Inability to lie flat for 20-25 minutes during an imaging session. 10. Pregnant or breastfeeding patients. 11. Medical or psychiatric co-morbidities that, in the opinion of the treating physician, would prevent the patient from successfully participating in the study.
Conditions Major Depressive Disorder (MDD), Schizop...
Phase Not Applicable
Enrollment 320
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is an observational study aiming to screen biomarkers associated with the diagnosis and treatment outcomes of severe mental disorders (MDD/major depressive disorder, SZ/schizophrenia, BD/bipolar disorder) through 7T ultra-high-field magnetic resonance multimodal imaging and visual perception assessment, thereby optimizing the objectivity and precision of clinical diagnosis and treatment. I. Core Research Objectives 1. Clarify the specific changes in visual perception behavior and brain imaging (metabolism, functional connectivity) of patients with severe mental disorders before and after treatment. 2. Establish a biomarker system related to disease diagnosis and treatment outcomes to make up for the limitation of current clinical reliance on phenomenological diagnosis. II. Study Subjects and Inclusion/Exclusion Criteria 1. Recruitment Scope * Patient group: MDD, SZ, and BD patients diagnosed in the Department of Psychiatry, the Second Affiliated Hospital of Zhejiang University School of Medicine. * Healthy control group: Healthy individuals without a history of mental illness recruited from the general population. 2. Key Criteria * Inclusion: Aged 18-45 years; meeting the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) diagnostic criteria (for the patient group); no organic brain injury or severe physical illness; signing the informed consent form. * Exclusion: Organic brain diseases; severe physical illnesses (e.g., tumors); internal metal implants (e.g., cardiac pacemakers); claustrophobia or inability to tolerate MR examinations; pregnancy, etc. III. Core Study Procedures 1. All participants will undergo 2 sessions of 7T MRI scans (including MRS, fMRI, and other multimodal sequences), focusing on the MT+ brain region and V1 brain region respectively, with the scan order randomly balanced. 2. During the interval between the two MRI scans, participants will complete visual psychophysical experiments, cognitive function tests (e.g., BDT test), and clinical symptom collection. 3. The study will not interfere with routine clinical treatment and strictly adheres to the ethical standards of the Second Affiliated Hospital of Zhejiang University School of Medicine (Ethical Approval No.: 2025 Lun Shen Yan Di 0603). IV. Study Significance 1. Provide objective biomarkers for clinical practice to improve the accuracy of diagnosis and the scientificity of treatment effect evaluation for severe mental disorders. 2. Reveal the association mechanism between visual cortex-related brain networks and diseases, laying a theoretical foundation for precision diagnosis and treatment.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Concentration of gamma-aminobutyric acid (GABA) in visual cortex (Baseline and 4 weeks post-treatment)
  • Concentration of glutamate (Glu) in visual cortex (Baseline and 4 weeks post-treatment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-11-01
Completion: 2027-06-30
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 320 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine
Contact Information
Study Contact:
Zheng Lin
86-13757118261
Linzzr@126.com
Zheng Lin
86-13757118261
Linzzr@126.com
Second Affiliated Hospital, School of Medicine, Zhejiang
Interventions
N/A
Study Locations (1 sites)
Second Affiliated Hospital, School of Medicine, Zhejiang, Hangzhou, Zhejiang 310000 China
Eligibility Criteria
Inclusion Criteria: * Participants aged 18 to 45 years old at the time of enrollment * Male or female participants * For patients: A diagnosis of major depressive disorder (MDD), schizophrenia (SZ), or bipolar disorder (BD) based on DSM-5 criteria * For healthy controls: No history of any mental health disorders * No current severe medical illnesses or history of brain injury such as encephalitis * Ability to provide written informed consent by the participant or their guardian Exclusion Criteria: * History of head injury or brain diseases such as epilepsy * Presence of severe physical illnesses such as tumors or thyroid problems * Presence of metal implants in the body like pacemakers or brain devices * Fear of enclosed spaces (claustrophobia) or inability to undergo an MRI scan * Current pregnancy
Conditions Cardiovascular Risk Factors, Hypertensio...
Phase NA
Enrollment 220
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to evaluate cardiovascular risk factors, clinical characteristics, and outcomes in adult patients attending an outpatient cardiology clinic. The research focuses on identifying predictors of adverse cardiovascular events, optimizing risk stratification, and improving preventive strategies in routine clinical practice. Data will be collected from patients receiving standard cardiology care without altering their treatment. The results are expected to contribute to better understanding of cardiovascular risk profiles and to support improvements in clinical decision-making and patient management.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Other: Structured Cardiovascular Risk Management — Protocol-based clinical management including periodic evaluation and adjustment of antihypertensive, lipid-lowering, antidiabetic, and lifestyle interventions according to routine clinical practice guidelines.

Primary Outcomes

  • Change in systolic blood pressure (Baseline to 90 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-07-24
Completion: 2026-10-24
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 220 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Universidad Católica San Antonio de Murcia
Principal Investigators:
  • José Abellán Alemán, MD, PhD (STUDY_CHAIR) - Universidad Católica San Antonio de Murcia
Contact Information
Study Contact:
Julio César Núñez Farías, MD, MSc (Cardiology)
+56965860130
llaillai@yahoo.es
Julio César Núñez Farías, MD, MSc
+56965860130
llaillai@yahoo.es
CDIEM Medical Center - Outpatient Cardiology Clinic
Julio C Núñez Farías, MD, MSc
CDIEM Medical Center - Outpatient Cardiology Clinic
Interventions
  • Other: Structured Cardiovascular Risk Management — Protocol-based clinical management including periodic evaluation and adjustment of antihypertensive, lipid-lowering, antidiabetic, and lifestyle interventions according to routine clinical practice guidelines.
Study Locations (1 sites)
CDIEM Medical Center - Outpatient Cardiology Clinic, Santiago, Santiago Metropolitan Chile
Eligibility Criteria
Inclusion Criteria: * Age ≥18 years * Presence of at least one cardiovascular risk factor (hypertension, diabetes, dyslipidemia, obesity, or smoking) * Receiving outpatient clinical follow-up * Ability to provide informed consent Exclusion Criteria: * Severe clinical instability requiring hospitalization * Pregnancy * End-stage renal disease or dialysis * Inability to complete follow-up visits * Refusal to participate
Conditions HR+/HER2- Advanced or Metastatic Breast ...
Phase Not Applicable
Enrollment 14000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to fill the current gap in data regarding HR+/HER2- ABC 1L treatment patterns and outcomes in the real-world setting in China, especially in the context of the widespread application of CDK4/6is and the lack of sufficient evidence for ribociclib as a most recently marketed drug in the real-world setting.

Design

Study type: Observational Observational model: Cohort Time perspective: Retrospective

Primary Outcomes

  • Distribution of first-line treatment regimens (Up to 39 months)
  • Proportion of patients with treatment changes (Up to 39 months)
  • Time to treatment initiation, time to discontinuation, and time to next line therapy (Up to 39 months)
  • Proportion of patients by initial CDK4 6 inhibitor dose (Up to 39 months)
  • Proportion of patients with dose modifications of CDK4/6 inhibitor therapy (Up to 39 months)
  • Time to first dose modification of CDK4/6 inhibitor therapy (Up to 39 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-03-20
Completion: 2027-04-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 14000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Novartis Pharmaceuticals
Principal Investigators:
  • Novartis Pharmaceuticals (STUDY_DIRECTOR) - Novartis Pharmaceuticals
Contact Information
Study Contact:
Novartis Pharmaceuticals
+41613241111
novartis.email@novartis.com
Novartis Pharmaceuticals
Interventions
N/A
Study Locations (1 sites)
Novartis Investigative SIte, Bingjie, Beijing Municipality 100021 China
Eligibility Criteria
Inclusion Criteria: 1. Diagnosed with HR+/HER2- ABC: HR+ is defined as ER+ or PR+, and HER2+ is defined as immunohistochemistry 3+, or 2+ with positive in situ hybridization (amplification). Advanced or metastatic breast cancer is defined as having a documented inoperable clinical or pathological stage IIIB, IIIC, or IV, or the records indicating distant metastasis. 2. Initiation of 1L anti-cancer treatment between Jan. 1, 2024 and Jan. 1, 2027; Defined as having records of systemic anti-cancer treatment in disease course records or order records within 90 days after the initial diagnosis of ABC, and receiving the first dose between Jan. 1, 2024 and Jan. 1, 2027, as recorded in the NATDSS database. 3. Aged 18 years or older at the time of receiving the 1L treatment; Definition: The initiation date (index date) of 1L treatment is defined as the initiation date of systemic anti-cancer treatment for HR+/HER2- ABC first recorded in the database. Age will be preferentially calculated based on the date of birth (or year of birth) and the initiation date of 1L treatment in the database. If the birth information is not included in the database but shown in an "Age" field in the medical visit/hospitalization record associated with 1L treatment, this age field will be used as the basis for age. 4. At least 3 months of follow-up records after the initiation of 1L treatment. Defined as having at least one outpatient or inpatient medical visit record in the NATDSS at least 3 months after the index date. Exclusion Criteria: (1) Patients with any other concomitant invasive malignancies Defined as patients meeting any of the following conditions based on their diagnosis records in the cancer registry/medical database used for the study: 1. Within 5 years before the diagnosis of HR+/HER2- ABC, there is a diagnosis record of invasive malignancy other than breast cancer in the database (based on the International Classification of Diseases \[ICD\] diagnosis code or cancer registry code), and the diagnosis is not carcinoma in situ or benign/borderline tumor; 2. On the day of, or within 3 months after, the diagnosis of HR+/HER2- ABC, there is a new diagnosis record of invasive malignancy at another site (also based on the ICD diagnosis code or cancer registry code) indicating a concomitant active malignancy.